MiniCC with WW:
I'm going to do this on lunch break. I called WW to get some background on the issues that seem to be plaguing us:
1)First I ask him about this Jefferies report that came out this am. I pointed out that it seemed to me that IONS was being set up again for an "AEGR-like experience" and I went through the same issues that I posted earlier in this regard.
He noted that those two Jefferies analysts didn't know too much and that they have very unscientific information. He also noted that their information gathering was very suspect and it was on par with propaganda. He brought out the issue of how you ask a question and how that would direct your answer. And then how people could report their "info" from their "study." He noted that from his info when patient's parents are asked, "Would you like your child to receive an FDA approved drug for SMA or a genetic trial drug?" that their data showed a very heavy skewing of parents wanting their child to be taking the approved drug. He noted that if the question was asked devoid of the issue of an approved drug, and simply asked "would you like your child to try a new genetic drug in trials" for their child's SMA that the results would show a positive yes for the genetic drug wanting to be used. I asked him that with his exposure to BIIB were they highly committed to lauching this drug and really getting it out there? He noted most definitely. I ask if there was ANY chance that there would be a shortage of drug once it has been approved, or some type of possible logistical problem getting people on the drug. He noted that the DEFINITELY had more than enoough drug to meet demand and more as it stands now. There was no concern on IONS part in this regard. He reminded me that it is only a 12 mg dosing. He notes that they "have plenty of drug supply for the launching and thereafter" and this would definitely not be a problem. He further pointed out they witnessed BIIB going through every detail to the nth degree BIIB to get this drug out as quickly and as widely as possible....IONS was convinced of that(bodes well for further deals then IMO).
2)I asked again about a partner's preparedness when I went after GSK as a partner. I asked if he or people at IONS had witnessed GSK's committment to the TTR-amyloidosis drug? He noted "most definitely." I plugged after that and ask if GSK was keenly aware of what ALNY was saying and how they were conducting themselves in regards to preparation and aggressive launch of their own TTR-amyloidosis version of their drug after being approved. He noted that GSK had plenty of contacts and that IONS was constantly keeping them informed as well. He noted that GSK had a very great interst in getting this drug out and to market and he noted again about a 4 month head start on ALNY's drug. He also noted that the door was open for cardiac indication once they get data on the FAP portion of their study.
3)I asked him if there was any way that Castle would be also co-promoting the Akcea drugs? He noted "no" and that he felt that they at IONS were planning on waiting for a big pharma partner almost for sure when their indications for the drugs are able to be expanded to larger populations.
4)Asked about the Factor XI inhibitor and Bayer. He noted that there are as we already knew, three contenders with Bayer for the Factor XI inhibitor space. The IONS drug itself has been moving forward and he noted no trepidations or anticipated problems but that we would just have to wait and see how things go. At this time there is no moth-balling of the drug. He did note that Bayer also was very committed to studying the drugs prospects and hopeful for being able to us it.
I had several other questions but once I reach the 5 to 7 minute mark I want to let him go so as to not make where he doesn't want to return my calls in the future. t
They got $3 million yesterday from a CF foundation and they got notification today of a rapid review in Europe for their SMA drug. This is a great board now BTW. t
If you really believe in their deep-seated technology you don't want to see them bought out. They should be able to to in about $600 million a year within three to five years with their SMA drug. Look for news about their Type 2 and Type 3 data to come out before Sept 15th. Couple that with probably another $400 million for the two Akcea indications for their ApoC III inhibitor, add in another $400 for their Lp(a) inhibitor, and at least $600 million from their TTR amyloidosis inhibitor and you have $2,000,000,000 divided by 135,000,000 time 30 and you have about 444 per share and I don't think that is a stretch at all and we havev't even talked about the other 34 drugs in the pipeline. Wall Street will catch on fast once they realize the prime time use or INOS SMA drug. t
Look for approval of IONS SMA drug in both the US and the EU very soon. Also, there is really nothing to treat really high level of triglycerides. With IONS ApoC III inhibitor look for an approval of that drug for the two orphan indications. For a bigger populations for just elevated triglycerides that will take time. But within three years IONS should be grossing over a billion a year. By that time their 2.5 generation LICA form Lp(a) drug could also very well be approved. IMO by then the company should be given a P/E of at least 30. t
This is kind of a cool set up as long as Y keeps it going. Skybusted lost huge on PTLA and they got an FDA letter and no approval. Things will really start flying for IONS over the next 12 months. t
I can only get to this message board using my iPhone, but that is better than nothing and top shelf might ever find out about it. 😆
Cameron loves walking! He is even learning to kick a ball! He gets an injection this week in the clinical trial. He continues to impress us with his strength and we know the doctors will be as impressed when we see them this week. While we are there we are taking him to Sea World! Let's hope we all stay healthy!!!!!!!!
Looking forward to SMA drug approval. t
Juno Therapeutics receives notice from the FDA that a clinical hold has been placed on the Phase II clinical trial of JCAR015 (shares halted) (40.85 +0.88)
The co announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), known as the "ROCKET" trial. The clinical hold was initiated after two patient deaths last week, which followed the recent addition of fludarabine to the pre-conditioning regimen.
Juno has proposed to the FDA to continue the ROCKET trial using JCAR015 with cyclophosphamide pre-conditioning alone. In response, the FDA has requested that Juno submit, as a Complete Response to the Clinical Hold: a revised patient informed consent form, a revised investigator brochure, a revised trial protocol, and a copy of the presentation made to the agency yesterday. Juno will submit the requested information to the FDA this week.
Juno's trials and plans for its other CD19-directed CAR-T cell product candidates, including JCAR017, are not affected.
This type of "info" that you "release" here show's exactly how you have been exposed as a person with really no info. I believe that deep down you are afraid that IONS is going to make it really big and you have now gone on the war path against it. NO??? Everyone take a look at your "timely" post about what type of tough straights BIIB is in and how terrible they are going to do and how bad their MS drugs are doing and then go look up their share price today to see UP OVER $50 today. You might want to look at your own shoes before you lecture someone about deep doo doo. And people here can thank you for the "tip" on BIIB. t
Check again SFB's and maybe put up the last quote for each company in regards to share price. I myself wouldn't brag about a one day movement as the market is complicated and many things go on over a day's worth of trading. It is really the intermediate and long term that matters. But since you are a SFB's that brought up the issue....why don't you put out the closing price of each stock? Frankly if I had recommended a stock that took a reverse stock split of 10:1 I'd never show my face here again, or at least not brag....but you're a different kind of animal. t
Again an exaggeration by you and you are fixated on old news. And please pull up the link to back up your delusion. Why don't you go after that oil analysts at Goldman Sachs that four years ago said oil was going to $200 per barrel? You have no ability to think in the abstract. Skybuster00, carry on captain!!t
WOW you really wigged out......no sound arguments. You need to change your name to skybuster00 to reflect your true knowledge!!!! t
Also, why don't you tell the full story. 75% of GILD success has occurred over the last two years with their blockbuster HepC drugs. They however have really strained the medical system with that huge price to be paid for so many people who have Hep C. The other real truths are that the drug was priced so high that they have been forced to discount it to the VA and other insurances companies. The other disgusting thing about that was that if you live in India you can get full treatment with their Hep C drug for $900.......how about maybe pointing that out??? Also, the market isn't too impressed about GILD lately. That being that there are questions about their being able to keep that monetary projection into the future with new products....how about pointing that out?? Also, ARIA, IDRA, VRTX, EXEL and many others started at the same time or around the same time as IONS did. How about pointing that out? How about a comparison of IDRA with IONS in regards to: cash on hand, deals with big pharma, pipeline etc??? I would rather take my chances with a company that hasn't had their value fully reflected than to go with GILD. Though GILD is not a bad investment here. The main question is, do they have the potential that IONS has over the next three years? I say NO. Especially when my genius from skybuster gets over to their website and the company and scorches them for their extremely high prices and price differentials between countries for the Hep C drugs, their lack of diversity of pipeline making it where analysts are demanding they do something or buy something because of this fear. t
I'd immediately set out ot the GILD board and chastise them about the cost fo their medication and how you are afraid that we will run out of money with their charging orphan drug prices for a mainstream illness. t
You must be talking to Aaron Reames....wasn't my call. You seem to be getting weirder and weirder. Also hint at being...won't say on this screen but what you said about the SMN drug, the patient's, and the judgmental statement was somewhat frightening. Maybe you could call that Aaron guy and tutor him on how to be perfect. t